Biologically Focused Therapy of Treatment-Refractory MDS Patients

Trial ID or NCT#

NCT05245032

Status

not recruiting iconNOT RECRUITING

Purpose

This non interventional study examines the feasibility of using patient specific therapeutic screening method, ex vivo to enhance current treatment recommendations in a clinically feasible time frame of 30 days.

Official Title

Biologically Focused Therapy of Treatment Refractory MDS Patients

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
  1. * Provide informed consent;* Myelodysplastic syndrome as defined by WHO classification (see Appendix 2), or MDS/MPN with \>= 5% blasts in the bone marrow or peripheral blood, including chronic myelomonocytic leukemia (CMML) 1 and 2 by WHO classification* Relapsed/refractory disease, defined as failed or are ineligible for hypomethylating agent therapy* Cytogenetics reported
Exclusion Criteria:
  1. * Hypoplastic MDS* Patients without adequate marrow samples for ex vivo analysis
View All Criteria
Show Less

Investigator(s)

Peter Greenberg
Peter Greenberg
Hematologist-Oncologist
Professor of Medicine (Hematology), Emeritus

Contact us to find out if this trial is right for you.

Contact

Jack Taw
650-723-2781

View on ClinicalTrials.gov